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Abstract a-Synuclein has been implicated in the patho-
genesis of Parkinson’s disease (PD). Previous studies have
shown that a-synuclein is involved in the regulation of
dopamine (DA) metabolism, possibly by down-regulating
the expression of tyrosine hydroxylase (TH), the rate-lim-
iting enzyme in DA biosynthesis. In this study, we
constructed a-synuclein stably silenced MN9D/a-SYN
-
cells by vector mediated RNA interference and examined
its effects on DA metabolism. We found that there were no
signiﬁcant differences in TH protein and mRNA levels
between MN9D, MN9D/a-SYN
- and MN9D/CON cells,
suggesting that silencing a-synuclein expression does not
affect TH gene expression. However, signiﬁcant increases
in phosphorylated TH, cytosolic 3, 4-dihydroxyphenylala-
nine (L-DOPA) and DA levels were observed in MN9D/a-
SYN
- cells. Our data show that TH activity and DA bio-
synthesis were enhanced by down-regulation of a-
synuclein, suggesting that a-synuclein may act as a nega-
tive regulator of cytosolic DA. With respect to PD
pathology, a loss of functional a-synuclein may result in
increased DA levels in neurons that may lead to cell injury
or even death.
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Introduction
a-Synuclein is a 140-amino acid protein, which has been
implicated in the pathogenesis of Parkinson’s disease (PD)
[20, 30]. Previous studies have shown that a-synuclein
mutations (A53T, A30P, E46K) are associated with some
autosomal-dominant PD [14, 15, 27] and that aggregated a-
synuclein is the major component of Lewy bodies and
Lewy neurites, pathological hallmarks of PD [2, 21, 34].
Although the normal function of a-synuclein and its role in
the pathogenesis of PD remain unclear, several hypotheses
have been proposed based on its physical properties or
interacting partners [17–19, 25, 28, 31, 36]. One theory
suggested that a-synuclein might be linked to PD via the
regulation of dopamine (DA) homeostasis [1, 18, 25, 31,
41]. Several studies have shown that a-synuclein may be
involved in regulating the biosynthesis, vesicular storage
and release, as well as reuptake of DA [3, 9, 26, 32, 33, 38,
40, 42]. However, some of these ﬁndings remain contro-
versial. It has also been reported that a-synuclein may
down-regulate the gene expression of tyrosine hydroxylase
(TH), the rate-limiting enzyme involved in DA biosyn-
thesis [3, 42]. Others report that a-synuclein regulates DA
biosynthesis by reducing TH activity [26]. Another study
showed that the tyrosine-mediated enhancement of phos-
phorylated TH in nigrostriatal DA neurons was inhibited in
a-synuclein knockout mice, suggesting that a-synuclein
may either enhance TH phosphorylation or hinder TH
inactivation during accelerated neuronal activity [9].
Although it has been established that a-synuclein plays an
important role in enhancing TH activity, conﬂicting reports
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role of a-synuclein in regulating DA metabolism.
RNA interference (RNAi) is a new strategy for silencing
gene expression that uses short double-stranded (ds) RNA
to mediate the degradation of sequence speciﬁc mRNA
[10–12]. It has been reported that introducing small inter-
fering RNAs (siRNAs) or short hairpin RNA (shRNA) into
mammalian cells could speciﬁcally silence the expression
of target genes [7, 23]. The high speciﬁcity, efﬁciency and
convenience of this technique means that it is a powerful
tool for studying gene function.
In the present study, we silenced the expression of a-
synuclein using vector mediated RNAi in dopaminergic
MN9D cells and examined the effect of down-regulation of
a-synuclein on TH and DA biosynthesis.
Materials and Methods
Construction of shRNA Expression Plasmids
Short hairpin RNA were designed to target speciﬁc regions
of mouse a-synuclein mRNA (GenBank accession no.
AF179273). We identiﬁed two 19-nucleotide stretches
within the coding region of the a-synuclein gene that were
40–50% GC rich, located within one exon and unique
within the mouse genome. A nine-nucleotide loop structure
was designed to form the hairpin. We designed three sets of
oligonucleotides as instructed by the BLOCK-iT
TM
Inducible H1 RNAi Entry Vector Kit (Invitrogen, Carlsbad,
CA, USA): SH1/a-SYN: 50-CACCGAGCAAGTGACAA
ATTTGTTCAAGAGACAACATTTGTCACTTGCTC-30
(forward), 50-AAAAGAGCAAGTGACAAATGTTGTCT
CTTGAACAACATTTGTCACTTG CTC-30 (reverse);
SH2/a-SYN: 50-CACCAGGCTACCAAGACTATGAGTT
CAAGAG ACTCATAGTCTTGGTAGCC-30 (forward),
50-AAAAGGCTACCAAGACTATGA GTCTCTTGAAC
TCATAGTCTTGGTAGCCT-30 (reverse); and SH/CON:
50-CACCGGATCGCCAGAACAAGTATTTCAAGAGAA
TACTTGTTCTGGCGATCC-30 (forward), 50-AAAAG-
GATCGCCAGAACAAGTATTCTCTTGAAATACTTGT
TCTGG CGATCC-30 (reverse). Single-stranded (ss) DNA
oligos(BioSia,Co.,Ltd,Shanghai,China)weresynthesized.
Equal amounts of each pair of ss oligos were annealed to
generate ds oligos. The ds oligos were inserted into the
pENTRTM/H1/TOvector(Invitrogen)usingT4DNAligase
and transformed into One Shot
 TOP10 chemically com-
petentEscherichiacoli(Invitrogen).Thetransformantswere
veriﬁedbyPCRandsequencing.Thepositiveplasmidswere
named pSH1/a-SYN, pSH2/a-SYN and pSH/CON,
respectively.
Cell Culture
The MN9D dopaminergic cell line was generated by
fusion of rostral mesencephalic neurons from embryonic
C57BL/6J (embryonic day 14) mice with N18TG2 neu-
roblastoma cells [8] (gift from Dr Bastian Hengerer,
Novartis AG). Cells were cultured in DMEM/F12 media
supplemented with 10% neonatal calf serum (GIBCO
BRL, Grand Island, NY, USA; pH 7.2) and incubated at
37C in an atmosphere of 5% CO2. MN9D cells
endogenously express a-synuclein and TH, and produce
measurable levels of DA.
Transfection and Selection
MN9D cells were transfected with pSH1/a-SYN, pSH2/a-
SYN, pSH/CON or pcDNA3.1 containing human wild-type
(WT) a-synuclein cDNA (constructed in our laboratory).
For stable transfection of pSH1/a-SYN, pSH2/a-SYN and
pSH/CON, cells were seeded in 6-well tissue culture plates
pre-coated with poly-L-lysine (Sigma, St Louis, MO, USA)
at 80–85% conﬂuency. Transfections were performed
using Lipofectamine
TM 2000 (Invitrogen) according to the
manufacturer’s instructions. Four to six hours after trans-
fection, the media was replaced with fresh growth media.
The following day, cells were trypsinized and replated into
a larger sized tissue culture format. Stably transfected
MN9D cells were selected using 400 lg/ml Zeocin
TM
(Invitrogen) for 12 days. The Zeocin
TM resistant clones
were then selected and expanded. Cells were maintained
with media containing 50 lg/ml Zeocin
TM. Seventy-two
hours post-transfection, cells transfected with pcDNA3.1
containing human WT a-synuclein cDNA were collected
and named MN9D/a-SYN
+.
RNA Isolation, RT-PCR and Real-time RT-PCR
Total RNA was extracted from pSH1/a-SYN, pSH2/a-SYN
and pSH/CON stably transfected MN9D cells and MN9D/a-
SYN
+ cells using Trizol reagent. First-strand cDNA was
synthesized from 5 lg of total RNA, using the Super-
Script
TM First-strand synthesis System for RT-PCR
(Invitrogen).ThereactionmixtureforPCRconsistedof1 ll
of cDNA template, 17 ll of sterile ddH2O and 10 pmol
(1 ll) of each speciﬁc primer. The following primers were
used: a-synuclein: 50-ATAAGAATGCGGCCGCATGGAT
GTATTCATGAAAG-30 (forward) and 50-CCGCTCGAGG
CTTCAGGTTCGTAGTCTTGA-30 (reverse). As an inter-
nal control, b-actin cDNA was co-ampliﬁed using the
following primer sequences: 50-CCCATCTACGAGGGC-
TACGC-30 (forward) and 50-AGGAAGGAGGGCTGGAA
CA-30 (reverse).EachPCRwasstartedbypredenaturationat
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12396C for 3 min. Each PCR cycle consisted of 94C for 30 s,
50C for 55 s and 72C for 55 s, followed by a ﬁnal 10 min
extension at 72C. PCR ampliﬁcation was carried out for 35
cycles for a-synuclein and 22 cycles for b-actin using a
Perkin–Elmer DNA thermal cycler 480 (Applied Biosys-
tems, Foster City, CA, USA).
The reaction mixture (20 ll) for real-time PCR consisted
of 10 ll SYBR GREEN PCR Master Mix (Applied Bio-
systems), 0.5 ll of cDNA template, 0.4 ll of each speciﬁc
primer (10 lM) and 9.7 ll of sterile ddH2O. The following
primers were used: a-synuclein: 50-TGACGGGTGTGA-
CAGCAGTAG-30 (forward) and 50-CAGTGGCTGCTGC
AATGC-30 (reverse); TH: 50-CAGCCCTACCAAGATCA
AAC-30 (forward) and 50-TACGGGTC AAACTTCACA-
GA-30 (reverse); and b-actin: 50-ACCACCATGTACCCAG
GCATT-30 (forward) and 50-CCACACAGAGTACTTGC
GCTCA-30 (reverse). Quantitative PCR was performed in
duplicate or triplicate using a 7300 real-time PCR thermal
cycler (Applied Biosystems). Each reaction was started by
50C for 2 min, 95C for 10 min and 96C for 3 min, fol-
lowed by 40 cycles of 94C for15 s, 59Cfor 20 s and 72C
for 30 s.
Immunoﬂuorescence Staining
Cells were washed with 0.01 M PBS, ﬁxed in 4% para-
formaldehyde (30 min), permealized with 0.5% Triton-X
(20 min) and blocked in 5% normal goat serum (30 min).
Samples were incubated with a speciﬁc monoclonal anti-
body against a-synuclein (2E3; 1:1000) (gift from Dr Shun
Yu, Xuanwu Hospital, Capital Medical University, Beijing,
China) overnight at 4C. Cells were washed with 0.01 M
PBS and incubated with goat anti-mouse IgG conjugated to
cyanine 3 (Cy3
TM; 1:400, Sigma) at 37C for 30 min. After
a ﬁnal wash, cells were examined by ﬂuorescence
microscopy.
Cell Viability Assay
Cell viability was assessed using a MTT Kit (Promega, WI,
USA). Brieﬂy, the transfected MN9D cells were plated into
96-well plates (1.0 9 10
4 cells per well) and cultured for
24 h prior to the assay. Sixteen wells were measured for
each stably transfected MN9D cell line.
Western Blot Analysis
Lysates of MN9D cells were prepared as previously
described [39]. Protein concentrations were determined
using BCA relative to BSA protein standards according
to the manufacturer (Pierce, Rockford, IL, USA). Whole
cell protein extracts were resolved by SDS-PAGE and
electrophoretically transferred to nitrocellulose mem-
brane. Prestained protein standards were used to
determine the relative molecular mass of proteins. The
membranes were blocked in 5% nonfat dry milk in Tris-
buffered saline, then incubated with the TH speciﬁc
monoclonal antibody (1:5000, Sigma) or a-synuclein
speciﬁc monoclonal antibody (2E3; 1:1000) at room
temperature for 3 h, followed by a 1-h incubation with a
peroxidase-conjugated secondary antibody (1:5000,
ZhongShan, Beijing, China) at room temperature. The
blots were washed and immunodetection was carried out
by chemiluminescence using SuperSignal (Pierce). Blots
were then stripped and re-probed with an antibody
against b-actin (1:500, Zhongshan). Blots were scanned
using Kodak Image Station (440 CF; Kodak, Rochester,
MN, USA) and the optical densities of the bands relative
to b-actin within each lane were obtained.
HPLC for Assaying DA and 3, 4-
Dihydroxyphenylalanine (L-DOPA) Levels
MN9D cells were collected and re-suspended in HPLC
buffer consisting of 0.1 N perchloric acid, 0.3 mM
EDTA and 0.1% L-lysine. Cells were freeze-thawed three
times, then centrifugated at 15,000 g for 15 min at 4C
to remove particulates. The supernatants were collected
and stored at -80C until analysis. Brieﬂy, the super-
natant samples (20–50 ll) were injected onto a Phase II
Column (ODS, 3.2 9 100 mm cartridge, U3.2 lm, Bio-
analytical Systems, Inc, USA). The mobile phase
consisted of 0.05 M CH3COONa, 0.05 M citric acid,
1 mM sodium octyl sulfate, 5 mM TEA, 0.075 mM
Na2EDTA and 10% methanol (v/v), pH 2.7. The mobile
phase was pumped through the system at 0.4 ml/min
using a PM-80 pump (Bioanalytical Systems, Inc).
Compounds were detected and quantiﬁed with an LC-4C
detector (Bioanalytical Systems, Inc). The limit of
detection for DA was 2 nmol/20 ll. Peaks were identi-
ﬁed by retention times set to known standards.
Tyrosine hydroxylase activity was assessed by mea-
suring the accumulation of L-DOPA within cells treated
with the aromatic L-amino acid decarboxylase (AADC)
inhibitor n-hydroxybenzylhydrazine dihydrochloride
(NSD-1015) and measured by HPLC as described above.
Brieﬂy, MN9D cells were cultured in 12-well tissue
culture plates, washed twice in artiﬁcial CSF (ACSF
containing 147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2
and 1.0 mM MgCl2) and equilibrated for 20 min at 37C
before addition of 200 lM NSD-1015 in ACSF for
30 min. ACSF samples were collected and assayed by
HPLC as described above.
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ANOVA followed by Bonferroni post hoc multiple com-
parisons were used to examine the signiﬁcance between
differences among the experimental groups. A value of
p\0.05 was considered to be statistically signiﬁcant. All
data are expressed as mean ± SE.
Results
Construction of the shRNA Expression Plasmids
After synthesis, each pair of the ss oligos was annealed to
generate ds oligos. The annealing efﬁciency was analyzed
by 4% agarose gel electrophoresis. Each ds oligo annealing
reactant showed a clearly detectable molecular weight band
around 50 bp, as expected for the length of the designed ds
oligos. The 50 bp bands were brighter than the corre-
sponding lower molecular weight band, which represented
the unannealed ss oligos in the annealing reactant. These
data indicate that each pair of ss oligos annealed effectively
to form ds oligos. The ds oligos were ligated with linear-
ized pENTR
TM/H1/TO vectors and the positive clones
were expanded and veriﬁed by PCR. Bands near 350 bp
were found in all PCR reactants, indicating that the ds
oligos were ligated into the pENTR/H1/TO vectors. Fur-
ther analysis by sequencing conﬁrmed that the orientation
and sequence of the inserted ds oligos were correct.
a-Synuclein Expression in MN9D Transfected Cells
The gene expression of a-synuclein in the transfected
MN9D cells was assayed by RT-PCR, real-time RT-PCR,
immunoﬂuorescence and Western blot. RT-PCR analysis
revealed that a-synuclein mRNA levels were decreased in
pSH2/a-SYN-transfected MN9D cells compared with
MN9D and pSH/CON-transfected MN9D cells (Fig. 1a).
However, a-synuclein mRNA levels in pSH1/a-SYN-
transfected cells were not signiﬁcantly different to levels
observed in control MN9D and pSH/CON-transfected
MN9D cells (Fig. 1a). These data suggest that a-synuclein
expression may be inhibited by transfection with pSH2/a-
SYN. In addition, real-time RT-PCR revealed that a-syn-
uclein mRNA levels in pSH2/a-SYN-transfected cells
(9.8 ± 2.4%) were signiﬁcantly lower than in MN9D and
MN9D/CON-transfected (81.6 ± 4.9%) cells (Fig. 1b).
The immunoﬂuorescence data also indicated that a-syn-
uclein gene expression was down-regulated in pSH2/a-
SYN-transfected cells (Fig. 1c). Weak immunoﬂuores-
cence staining was observed in pSH2/a-SYN-transfected
cells compared to strong a-synuclein staining in control
MN9D, pSH/CON-transfected and pSH1/a-SYN-transfec-
ted MN9D cells. Furthermore, western blot analysis
revealed that a-synuclein protein levels were signiﬁcantly
lower in pSH2/a-SYN-transfected cells (0.150 ± 0.004)
than in MN9D cells (0.401 ± 0.038) (Fig. 1d, e). Thus,
a-synuclein expression was inhibited after transfection of
MN9D cells with pSH2/a-SYN. These data suggest that
SH2/a-SYN was an effective siRNA sequence and that
a-synuclein expression was stably silenced in pSH2/
a-SYN-transfected MN9D cells. The pSH2/a-SYN and
pSH/CON stably transfected cells were then named
MN9D/a-SYN
- and MN9D/CON, respectively.
Effects of Silencing a-Synuclein Expression on Cell
Viability
No signiﬁcant differences in cell morphology were
observed between the three groups of MN9D cells (data not
shown). As shown in Fig. 2, the cell viability of MN9D/a-
SYN
- cells was signiﬁcantly decreased compared with
control MN9D and MN9D/CON cells [n = 5, F =
421.457, df(total) = 14, **p\0.001 compared with
MN9D cells, **p\0.001 compared with MN9D/CON
cells]. Cell viability was decreased by 58.3 and 50% in
MN9D/a-SYN
- cells (0.091 ± 0.006) compared with
MN9D (0.217 ± 0.012) and MN9D/CON (0.189 ± 0.005)
cells, respectively (Fig. 2). These data suggest that a-syn-
uclein may be important for the viability of MN9D cells.
TH Expression and Activity in MN9D Transfected
Cells
Previous studies have reported that TH expression may be
down-regulated by over-expression of a-synuclein in
MES23.5andM17cells[3,42].Here,weexaminedwhether
a similar effect occurred after the silencing of a-synuclein
expression in MN9D/a-SYN
- cells. TH mRNA, protein and
phosphorylationlevelsweremeasuredbyreal-timeRT-PCR
and Western blot analysis, respectively. Real-time RT-PCR
showed that there were no signiﬁcant differences in TH
mRNA levels between MN9D, MN9D/CON (116.00 ±
10.23%),MN9D/a-SYN
-(135.89 ±14.58%)andMN9D/a-
SYN
+ (85.67 ± 5.55%) cells (Fig. 3a). These observations
show that silencing a-synuclein expression did not alter TH
gene expression, suggesting that a-synuclein does not reg-
ulate expression of TH. Similar TH protein levels were
observed in MN9D, MN9D/CON (103.55 ±0.84%),
MN9D/a-SYN
- (126.40 ± 10.81%) and MN9D/a-SYN
+
(83.89 ± 4.06%)cellsbyWesternblotanalysis(Fig. 3b, c).
However, TH phosphorylation levels were signiﬁcantly
increased in MN9D/a-SYN
- (157.63 ± 8.36%) cells
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123Fig. 1 Inhibition of a-synuclein expression in pSH2/a-SYN-trans-
fected cells. (a) a-Synuclein mRNA levels were measured by RT-
PCR. Lane 1 pSH1/a-SYN-transfected MN9D cells; Lane 2 pSH2/a-
SYN-transfected MN9D cells; Lane 3 pSH/CON-transfected MN9D
cells; Lane 4 MN9D cells; Lane 5 100 bp DNA ladder. (b) Statistical
analysis of a-synuclein gene expression by real-time RT-PCR. a-
Synuclein mRNA levels were decreased by approximately 90% in
pSH2/a-SYN-transfected cells compared with normal MN9D cells
[n = 5, F = 216.167, df(total) = 14, **p\0.001 compared with
MN9D cells, **p\0.001 compared with MN9D/CON cells]. a-
Synuclein mRNA levels were not signiﬁcantly different in pSH1/a-
SYN-transfected cells compared with MN9D and MN9D/CON cells.
(c) Immunoﬂuorescence staining of normal MN9D cells (a) and
MN9D cells transfected with pSH1/a-SYN (b), pSH/CON (c) and
pSH2/a-SYN (d) using an antibody against a-synuclein. Strong a-
synuclein staining was observed in MN9D, pSH1/a-SYN-transfected
and pSH/CON-transfected MN9D cells, whereas weak staining was
observed in pSH2/a-SYN-transfected MN9D cells. Bar = 50 lm. (d)
Western blot analysis of a-synuclein protein levels. Lane 1 MN9D
cells; Lane 2 MN9D/CON cells; Lane 3 MN9D/a-SYN
- cells. (e)
Statistical analysis of a-synuclein protein levels in MN9D, MN9D/
CON and MN9D/a-SYN
- cells using the linear density ratio of a-
synuclein/b-actin. a-Synuclein protein levels were signiﬁcantly
decreased in MN9D/a-SYN
- cells (0.150 ± 0.004) compared with
MN9D (0.401 ± 0.038) and MN9D/CON (0.321 ± 0.011) cells
[n = 5, F = 162.034, df(total) = 14, **p\0.001 compared with
MN9D cells, **p\0.001 compared with MN9D/CON cells]
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123compared with MN9D and MN9D/CON (97.45 ± 5.06%)
cells, and signiﬁcantly decreased in MN9D/a-SYN
+ cells
(20.36 ± 2.86%) (Fig. 3b, d). To directly assess TH activ-
ity, we used NSD-1015 to inhibit AADC, thereby blocking
the conversion of L-DOPA to DA. We found that L-DOPA
levels were increased in MN9D/a-SYN
- cells (266.33 ±
11.05 nmol/l)comparedwithMN9D(121.92 ± 5.61 nmol/l)
and MN9D/CON (124.89 ± 8.94 nmol/l) cells (Fig. 4). In
contrast, a signiﬁcant decrease in L-DOPA levels was
observed in MN9D/a-SYN
+ cells (41.14 ± 3.89 nmol/l).
Since accumulation of L-DOPA could only occur if TH
actively converted tyrosine to L-DOPA, these data suggest
that TH activity was increased in MN9D/a-SYN
- cells and
diminished in cells over-expressing a-synuclein. These data
support the hypothesis that silencing a-synuclein expression
does not affect TH gene expression but can enhance TH
activity by increasing TH Ser40 phosphorylation.
Fig. 3 Effects of silencing a-synuclein expression on TH and
phospho-Ser40-TH levels. (a) Statistical analysis of TH gene
expression by real-time RT-PCR. Differences in TH mRNA levels
between the transfected MN9D cells were not statistically signiﬁcant
(n = 5). (b) Western blot analysis of TH, phospho-Ser40-TH and b-
actin protein levels. Lane 1 normal MN9D; Lane 2 MN9D/CON;
Lane 3 MN9D/a-SYN
-; Lane 4 MN9D/a-SYN
+ cells. (c) Statistical
analysis of TH protein levels in MN9D, MN9D/CON, MN9D/a-
SYN
- and MN9D/a-SYN
+ cells using the linear density percent of
TH/b-actin. No signiﬁcant differences in TH protein levels were
observed between the transfected MN9D cells (n = 5). (d) Statistical
analysis of phospho-Ser40-TH protein levels in MN9D, MN9D/CON,
MN9D/a-SYN
- and MN9D/a-SYN
+ cells using the linear density
percent of phospho-Ser40-TH/TH. Phospho-Ser40-TH protein levels
were signiﬁcantly increased in MN9D/a-SYN
- cells and signiﬁcantly
decreased in MN9D/a-SYN
+ cells compared with MN9D and MN9D/
CON cells [n = 5, F = 84.505, df(total) = 19, **p\0.001 MN9D/
a-SYN
- cells compared with MN9D cells, **p\0.001 MN9D/a-
SYN
- cells compared with MN9D/CON cells; **p\0.001 MN9D/
a-SYN
+ cells compared with MN9D cells, **p\0.001 MN9D/a-
SYN
+ cells compared with MN9D/CON cells]
Fig. 2 Effectsofsilencinga-synucleinexpressiononcellviability.Cell
viabilitywasmeasuredusinganMTTassay.Cellviabilitywasdecreased
in MN9D/a-SYN
- cells compared with MN9D and MN9D/CON cells
[n = 5, F = 421.457, df(total) = 14, **p\0.001 compared with
MN9D cells, **p\0.001 compared with MN9D/CON cells]
1406 Neurochem Res (2008) 33:1401–1409
123Effects of Silencing a-Synuclein Expression on DA
Levels
To assess differences in cytosolic DA levels between the
transfected MN9D cells, we prepared cell extracts and mea-
sured DA content by HPLC with electrochemical detection.
As shown inFig. 5, DAlevels weresigniﬁcantlyincreasedin
MN9D/a-SYN
- cells compared with MN9D and MN9D/
CON cells. The DA content was approximately 4.8-fold
higherinMN9D/a-SYN
-cells(834.72 ± 24.72 nmol/l)than
in normal MN9D cells (186.04 ± 31.38 nmol/l) and 2.4-fold
higher than in MN9D/CON cells (341.87 ± 46.25 nmol/l).
No signiﬁcant differences in DA content were observed
betweenMN9DandMN9D/CONcells(Fig. 5).Theseresults
indicate that silencing a-synuclein expression leads to an
increase in DA levels in MN9D cells.
Discussion
In the present study, we silenced the expression of a-syn-
uclein in MN9D dopaminergic cells by vector mediated
RNAi using the BLOCK-iT
TM inducible H1 RNAi entry
vector. This vector was selected for several reasons. Firstly,
the vector contains a kanamycin resistance gene for
selection in E. coli and a Zeocin
TM resistance marker to
allow generation of stable cell lines that express the shRNA
of interest. Secondly, the cloning site of the vector contains
a 4-nucleotide overhang on the 50 end of each DNA strand,
allowing directional cloning of the shRNA of interest.
Thirdly, the H1 promoter of the vector is recognized by
RNA polymerase III resulting in high-level, constitutive
expression of shRNA in most mammalian cell types. We
identiﬁed an effective targeting sequence for RNAi, which
localized in the C-terminal coding sequence of the mouse
a-synuclein gene, and used this to generate MN9D/a-
SYN
- cells in which the expression of a-synuclein was
stably silenced. Due to the endogenous expression of a-
synuclein and the dopaminergic characteristics of MN9D
cells, MN9D/a-SYN
- is a good cellular model for studying
the normal function of a-synuclein and examining its role
in PD pathogenesis.
We found that the cell viability of MN9D/a-SYN
- cells
was signiﬁcantly decreased compared with MN9D and
MN9D/CON cells, suggesting that loss of a-synuclein may
induce cell injury directly or indirectly. Based on sub-
sequent observations, we propose that a marked increase in
cytosolic DA levels may account for decreased cell via-
bility. DA can readily oxidize to generate hydrogen
peroxide, superoxide and reactive DA quinones [16, 35],
which are cytotoxic due to their inhibitory effects on the
mitochondrial respiratory system [5, 13]. In addition,
superﬂuous DA itself may be cytotoxic via inhibition of
mitochondrial complex I activity [4]. Thus, it is also pos-
sible that increased cytosolic DA levels induced
mitochondrial dysfunction resulting in decreased viability
in MN9D/a-SYN
- cells.
a-Synuclein may be involved in the regulation of TH,
the rate-limiting enzyme of DA biosynthesis. Several
Fig. 4 Effects of silencing a-synuclein expression on L-DOPA levels.
Cell lysates were prepared from transfected MN9D cells incubated in the
presenceof200 lMNSD-1015for30 min. L-DOPAlevelsweremeasured
by HPLC. L-DOPA levels were signiﬁcantly increased in MN9D/a-SYN
-
cells and signiﬁcantly decreased in MN9D/a-SYN
+ cells compared with
MN9D and MN9D/CON cells [n = 6, F = 140.944, df(total) = 23,
**p\0.001 MN9D/a-SYN
- cells compared with MN9D cells,
**p\0.001 MN9D/a-SYN
- cells compared with MN9D/CON cells;
**p\0.001 MN9D/a-SYN
+ cells compared with MN9D cells,
**p\0.001 MN9D/a-SYN
+ cells compared with MN9D/CON cells]
Fig. 5 Effects of silencing a-synuclein expression on DA levels.
Changes in DA levels were detected by HPLC. DA levels were
signiﬁcantly increased in MN9D/a-SYN
- cells compared with MN9D
and MN9D/CON cells [n = 6, F = 161.774, df(total) = 17,
**p\0.001 compared with MN9D cells, **p\0.001 compared
with MN9D/CON cells]. Differences in DA levels between the
MN9D and MN9D/CON cells were not statistically signiﬁcant
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123studies have shown that a-synuclein regulates TH gene
expression. In a-synuclein over-expressing MES23.5
dopaminergic cells, TH mRNA and protein levels were
signiﬁcantly reduced [42]. A similar effect was observed in
M17 dopaminergic cells transfected with WT a-synuclein
[3]. However, in the current study, no signiﬁcant differ-
ences in TH mRNA and protein levels were observed
between the four groups of MN9D cells. Interestingly, a
previous study using MN9D cells reported that a-synuclein
over-expression did not diminish endogenous TH levels
[26], which is consistent with our results. We propose that
the difference in TH levels between the present a-synuclein
silenced system and the previously described a-synuclein
over-expression system is mainly due to the different cell
types and not due to the different ways in which the cells
were manipulated.
Although TH protein levels remained unchanged in
MN9D/a-SYN
- cells, phosphorylation of TH at its Ser40
site was signiﬁcantly enhanced. Furthermore, L-DOPA
levels were signiﬁcantly increased after NSD-1015 treat-
ments. These results suggest that TH activity was enhanced
in MN9D/a-SYN
- cells, which is consistent with previous
reports [24, 26]. In addition, we also found that cytosolic
DA levels were signiﬁcantly increased in MN9D/a-SYN
-
cells. Our data show that TH activity was enhanced in a-
synuclein-silenced MN9D/a-SYN
- cells, and that this was
associated with an increase in DA biosynthesis followed by
increased cytosolic DA levels. The mechanisms by which
a-synuclein may regulate TH activity have not been elu-
cidated. It is known that only the phosphorylated form of
TH is active, and that the phosphorylation and dephos-
phorylation of TH are important in regulating DA
biosynthesis [29, 37]. Furthermore, phosphorylation of TH
at Ser40 results in the most prominent activation of TH
[37]. Thus, it has been suggested that a-synuclein regulates
TH activity by regulating the phosphorylation of TH [24].
Protein phosphatase 2A (PP2A), an important enzyme
required for dephosphorylation of TH, can be activated by
a-synuclein, resulting in a signiﬁcant increase in TH
dephosphorylation and reduction in TH activity [6]. In
addition, other factors may also be involved in the regu-
lation of TH phosphorylation by a-synuclein. For example,
14-3-3 enhances TH activity by binding directly to phos-
phorylated TH. a-Synuclein may directly interact with 14-
3-3 [22], thereby accelerating the dissociation of 14-3-3
from phosphorylated TH. a-Synuclein may also affect TH
activity by directly interacting with TH [26].
In conclusion, our data demonstrate that in PD pathol-
ogy, silencing of a-synuclein expression results in
enhanced TH activity and increased DA levels in neurons.
We propose that in cells that unable to remove excess DA
from the cytosol, DA itself and its oxidized products
including reactive oxygen species and reactive DA
quinones may lead to cell injury or even death. Further
understanding of the normal function of a-synuclein in
maintaining DA homeostasis may help to identify novel
preventative or therapeutic strategies for PD.
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